Why Pharma Manufacturing Digital Transformation Projects Fail After the Pilot

The hardest part of digitaltransformation in pharma is rarely building the technology. It is getting thetechnology to change what happens on the factory floor.

A pharmaceutical manufacturer launches apredictive-maintenance pilot.

The model works.

The dashboard looks impressive.

The accuracy numbers are good.

The operations team is interested.

The leadership team approves the nextphase.

And then, six months later, very littlehas changed.

The model is still running.

The pilot team is still talking about it.

But maintenance decisions are still beingmade the old way.

This pattern is more common than theindustry likes to admit.

The problem is not necessarily thetechnology.

It is the distance between asuccessful digital pilot and a capability that becomes part of dailyoperations.

That distance is where many pharmatransformation programs lose momentum.

The pilotlooked successful. So why did the transformation fail?

The traditional way of measuring a digital initiative is relativelysimple.

Did the model work?

Did the application work?

Did the integration work?

Did users like the interface?

Did the proof of concept demonstrate potential?

If the answer is yes, the project is often labelled successful.

But manufacturing does not create value through demonstrations.

It creates value through repeated execution.

A predictive-maintenance model creates value only when someone actsbefore equipment fails.

A quality analytics platform creates value only when it helps reducerecurring deviations or improve process control.

A production dashboard creates value only when it changes decisions.

An AI assistant creates value only when employees actually use itand trust the information it provides.

This creates a very different definition of success:

A digital transformation project is successful when the operatingsystem of the business changes—not when the software works.

That distinction is becoming increasingly important.

The numberstell an interesting story

Deloitte’s 2025 Smart Manufacturing and Operations Survey, covering600 manufacturing executives, found that 92% believe smart manufacturingwill be a major driver of competitiveness over the next three years.

The survey also reported measurable gains from smart manufacturinginitiatives:

·        10–20% improvement inproduction output

·        7–20% improvement inemployee productivity

·        10–15% unlocked capacity

Those are substantial outcomes.

But the same research reveals something else.

Only 29% of respondents reported using AI/ML at facility ornetwork level, while 23% were still piloting AI/ML.

For generative AI, 24% had deployed it at facility or network level,while 38% were still in pilot mode.

In other words:

The industry is not short of experimentation.

The harder problem is moving from experimentation to scaledoperating capability.

Pharma has an additional complication.

Manufacturing cannot be changed casually.

Every major process sits within a world of validation, quality,documentation, data integrity, training and regulatory oversight.

So the transformation has to move carefully.

But carefully does not have to mean slowly.

It means designing the change properly.

The biggest mistake: starting with technology

A typical transformation conversationbegins with technology.

“Should we implement a data lake?”

“Should we move to the cloud?”

“Should we use GenAI?”

“Should we build a digital twin?”

“Should we introduce computer vision?”

“Should we implement an AI platform?”

These are legitimate questions.

They are just not the first questions.

The first question should be:

Which operational problem isexpensive enough to solve and measurable enough to prove?

That sounds obvious.

In practice, it changes the entireproject.

Consider two possible transformationobjectives.

‍